EpiCast Report: Postherpetic Neuralgia – Epidemiology Forecast to 2022

Publisher Name :
Date:22-Oct-2013
No. of pages: 45

Postherpetic Neuralgia (PHN) is one of the most common complications of herpes zoster infection in elderly persons ages 60 years and older, worldwide. The main symptom of PHN is severe pain and allodynia (pain that results from a non-injurious stimulus to the skin). PHN is associated with a significant loss of activity levels and a reduced quality of life, particularly in the elderly. The strongest established risk factor for PHN is advancing age. Other possible risk factors for PHN include severity of acute herpes zoster pain, extent of rash, and duration of prodromal pain.

The number of incident cases of PHN in the 7MM will increase by 20.22% over the next decade, from 241,808 cases in 2012, to 290,694 cases in 2022. Ageand sex-specific incidence data for PHN and herpes zoster, as well as data for the proportion of herpes zoster patients developing PHN in the 7MM, were obtained or calculated from nationally-representative studies in each country to forecast the incident cases of PHN. To maintain a uniform methodology across the markets, GlobalData epidemiologists only used studies that defined PHN as pain persistent for three or more months.

Currently, there is no absolute preventative therapy for PHN. However, a vaccine is available to help prevent a herpes zoster infection; in turn, this vaccine helps reduce the incidence of PHN to an extent because PHN is the sequela of herpes zoster. The considerable increase in the aging population worldwide, coupled with the high risk for developing PHN in elderly herpes zoster patients are expected to impose a considerable burden on healthcare in the 7MM in future years.

Scope

  • The Postherpetic Neuralgia EpiCast Report provides an overview of the risk factors and global trends of postherpetic neuralgia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast (2012–2022) of the incident cases of postherpetic neuralgia segmented by age (in five-year increments beginning at age 50 and ending at age =85 years) and sex in the 7MM.
  • The postherpetic neuralgia epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global postherpetic neuralgia market.
  • Quantify patient populations in the global postherpetic neuralgia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for postherpetic neuralgia therapeutics in each of the markets covered.

EpiCast Report: Postherpetic Neuralgia – Epidemiology Forecast to 2022

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7

3 Epidemiology 8
3.1 Disease Overview 8
3.2 Risk Factors and Comorbidities 9
3.2.1 Elderly herpes zoster patients are almost 20 times more likely to develop PHN 9
3.2.2 Herpes zoster vaccine reduces the morbidity of herpes zoster and PHN 11
3.3 Global Trends 11
3.3.1 US 12
3.3.2 France 13
3.3.3 Germany 14
3.3.4 Italy 14
3.3.5 Spain 15
3.3.6 UK 16
3.3.7 Japan 17
3.4 Forecast Metodology 17
3.4.1 Sources Used 19
3.4.2 Forecast Assumptions and Methods 22
3.4.3 Sources Not Used 26
3.5 Epidemiological Forecast of Postherpetic Neuralgia (2012–2022) 27
3.5.1 Incident Cases of PHN 27
3.5.2 Age-Specific Incident Cases of PHN 28
3.5.3 Sex-Specific Incident Cases of PHN 30
3.5.4 Age-Standardized Incidence of PHN 32
3.6 Discussion 33
3.6.1 Epidemiological Forecast Insight 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 35

4 Appendix 37
4.1 Bibliography 37
4.2 About the Authors 40
4.2.1 Epidemiologists 40
4.2.2 Reviewers 40
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 42
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 42
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Disclaimer 44

List of Tables

Table 1: 7MM, Sources of PHN Incidence Data 18
Table 2: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012–2022 27
Table 3: 7MM, Incident Cases of PHN, by Age, Men and Women, N (Row %), 2012 29
Table 4: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N (Row %), 2012 31

List of Figures

Figure 1: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012–2022 28
Figure 2: 7MM, Incident Cases of PHN, by Age, Men and Women, N, 2012 30
Figure 3: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N, 2012 31
Figure 4: 7MM, Age-Standardized Incidence of PHN (per 1,000 Population), Ages ≥50 Years, Men and Women, 2012 33

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Croatia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 102
    BMI View: Heavy price cuts and margin restrictions within the pharmaceutical supply chain threaten to cause drug shortages and weaken the supply chain within Croatia, with product withdrawals expected and the HZZO braced for revolt from pharmacies and wholesalers. We forecast weak pharmaceutical market growth over the next decade, in light of Croatia's acceding to EU pressure to rein in its budget deficit. Liquidity issues and payment terms will remain unfavourable in 2014, but with Croatia's ec......
  • Kenya Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 106
    BMI View: Investment into Kenya's healthcare sector by pharmaceutical and medical device companies is an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between 2013 and 2018. However, we note that there are downside risks to our forecast, including government inefficiencies and the out-of-pocket characteristics of the market, which will act as challenges for companies looking for a rapid return on investment. Headline Expenditure Projections ? Pha......
  • Latvia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 107
    BMI View: Latvia's macroeconomic environment continues to improve at the same time as smooth transitions to a new currency and new Prime Minister. Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers looking towards exports to Russia to boost revenue. Headline Expenditure Pr......
  • Mexico Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 144
    BMI View: The lack of a unified reimbursement system, the absence of widespread private health insurance, relatively low healthcare spending and the promotion of generic drugs in Mexico will continue to undermine revenue-generating opportunities for innovative drugmakers. However, over the long term, healthier fiscal revenue due to energy reform will encourage the Mexican government to further increase public spending on medical services and improve national healthcare standards.. Headline Expen......
  • Thailand Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 115
    BMI View: Thailand offers several revenue earning opportunities to drugmakers due to its ageing population and the presence of a universal healthcare system that provides the population with access to healthcare. However cost containment policies and delays in patent approvals limit the attractiveness of the country to multinational pharmaceutical firms. Headline Expenditure Projections ? Pharmaceuticals: THB142.5bn (USD4.64bn) in 2013 to THB146.5bn (USD4.5bn) in 2014; +2.8% in local currency te......
  • Algeria Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: The Algerian government's aspirations to rebalance the pharmaceutical trade deficit and promote local generic production, whilst enhancing the country's competitiveness by stimulating the innovative biopharmaceutical industry as a strategic sector in the economy, will continue throughout Q414. A new memorandum of understanding between Pharmaceutical Research and Manufacturers of America (PhRMA) and Algeria's government indicates additional steps towards encouraging foreign direct inves......
  • Zambia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 61
    BMI View: The disparity between urban and rural healthcare provision in Zambia is showing signs of being addressed, with the recent opening of the first ever hospital to serve the district of Chienge. This, along with ongoing governmental training initiatives aimed at improving the skills of Zambian healthcare professionals, is likely to attract talent to the country. That said, speculation over President Sata's ill health, along with delays in the construction of 650 healthcare clinics across t......
  • Australia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 135
    BMI View: Over 300 drug formulations listed on the Pharmaceutical Benefits Scheme (PBS) will be subject to price reduction from October 1 2014, following the first simplified price disclosure (SPD) cycle in Australia. As a result, the prices of the affected drugs will be lowered by 20% on average, from those in April 2014. The Australian government continues to push price controls on pharmaceuticals. This is a reflection of the fact that high prices are no longer accepted by patients and nationa......
  • 2014 Market Research Report on Global Seaweed Fertilizer Industry
    Published: 19-Aug-2014        Price: US $3600 Onwards        Pages: 182
    This is a professional and depth research report on Global Seaweed Fertilizer industry. The report firstly introduced Seaweed Fertilizer basic information included Seaweed Fertilizer definition classification application industry chain structure industry overview;Then introduce North America (United States Canada etc) Europe (Ireland UK etc) Asia (China India etc) Rest of World Key players 2009-2014 Seaweed Fertilizer Capacity Production Price Cost Gross Production Value Gross Margin etc Dat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs